8.1. A “proof-of-concept”, double blind, parallel group study comparing the immune modulating and lipid lowering effects of beta-1,3/1,6-glucan (Immutol) with that of placebo (cellulose) in subjects with mild to moderate hypercholesterolemia (Biotec Pharmacon ASA, N-9008 Tromsø, Norway, 2003).
8.2. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-Glucan) in high-risk surgical patients (Babineau et al. 1994b)
8.3. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-Glucan) in high-risk surgical patients (Babineau et al. 1994a)
8.4. Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations (Phase III study) (Dellinger et al. 1999)
8.5. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan) (Felippe et al. 1993).
8.6. Beneficial effect of enhanced macrophage function in the trauma patient (Browder et al. 1990).
8.7. Effectiveness of beta-glucan collagen for treatment of partial-thickness burns in children (Delatte et al. 2001).